Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s
Hims & Hers Health, Inc. has announced a strategic collaboration with Novo Nordisk to expand its weight loss care offerings and align its U.S. approach with its global healthcare model. The partnership focuses on providing broader access to FDA-approved GLP-1 medications while enhancing patient-centered treatment options through the company’s digital health platform.
The move reflects a major shift in the evolving weight loss treatment landscape, where GLP-1 therapies have rapidly gained adoption for managing obesity and metabolic health. Hims & Hers hopes to increase access to clinically approved therapies while preserving cost and convenience for customers looking for cutting-edge weight management options by incorporating Novo Nordisk’s well-known drugs into its platform.
Health Technology Insights: https://healthtechnologyinsights.com/the-future-of-health-how-technology-is-shaping-patient-outcomes/
Through the new collaboration, the platform will offer several FDA-approved GLP-1 medications, including Ozempic® (semaglutide) injections and Wegovy® (semaglutide) tablets and injections. These medications are expected to become available on the platform later this month, giving providers and patients a wider range of treatment options supported by clinical evaluation and prescription oversight.
The CEO and co-founder of Hims & Hers, Andrew Dudum, stressed the value of teamwork in developing accessible healthcare solutions. Dudum stated, “We see tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications.” “Partnering with Novo Nordisk allows us to create a new model that works for everyday people while helping scale access to innovative medical treatments.”
The demand for GLP-1 therapies has grown significantly since Hims & Hers entered the weight loss market in 2023. During this time, the healthcare sector as a whole has also undergone substantial change, with novel treatment forms, better dosing flexibility, and increased access to FDA-approved drugs. These developments have encouraged many healthcare providers to shift toward branded therapies that offer well-established safety and efficacy profiles.
Hims & Hers will no longer advertise or market compounded GLP-1 drugs on its marketplace as part of its revised approach. Existing patients currently using compounded formulations will be given the opportunity to transition to FDA-approved therapies if healthcare providers determine the switch to be clinically appropriate.
Health Technology Insights: https://healthtechnologyinsights.com/top-strategies-for-targeted-outreach-in-medical-technology-marketing/
However, for a limited group of patients whose clinical needs cannot be met through commercially available GLP-1 treatments, the platform may still provide access to compounded semaglutide. In these cases, a licensed provider must determine that a compounded option is medically necessary.
Beyond medication access, Hims & Hers continues to offer integrated patient support services designed to improve long-term treatment outcomes. These services include direct access to healthcare providers, personalized nutrition guidance, and ongoing clinical monitoring to help patients stay on track with their weight management plans.
Looking ahead, Hims & Hers and Novo Nordisk plan to explore additional collaborations as new treatments become available. The partnership signals a broader shift toward integrated digital health platforms that combine pharmaceutical innovation, provider oversight, and personalized care to address growing global demand for effective weight loss therapies.
Health Technology Insights: https://healthtechnologyinsights.com/zendesk-healthcare-support-health-tech-reinvented/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
